Latest news with #ILUMYA
Globe and Mail
14-04-2025
- Health
- Globe and Mail
Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis
The Key Arthralgia Companies in the market include - Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others. DelveInsight's 'Arthralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Arthralgia, historical and forecasted epidemiology as well as the Arthralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Arthralgia Market Report: The Arthralgia market size is estimated to grow with a significant CAGR during the study period (2019-2032) Arthralgia affected women more than it did men, according to DelveInsight's data. For example, in Japan in 2021, there were about 34,000 cases of Arthralgia in males and about 39,000 in females. Key Arthralgia Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others Key Arthralgia Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab and others The Arthralgia epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases The Arthralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Arthralgia pipeline products will significantly revolutionize the Arthralgia market dynamics. Arthralgia Overview Arthralgia is a medical term used to describe pain or discomfort in one or more joints. Joints are the connections between bones, and arthralgia can affect various parts of the body, such as the knees, elbows, wrists, or shoulders. The pain associated with arthralgia can be caused by inflammation, injury, infection, or other underlying conditions affecting the joints. Arthralgia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Arthralgia Epidemiology Segmentation: The Arthralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Download the report to understand which factors are driving Arthralgia epidemiology trends @ Arthralgia Epidemiology Forecast Arthralgia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Arthralgia market or expected to get launched during the study period. The analysis covers Arthralgia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Arthralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Arthralgia Therapies and Key Companies Discover more about therapies set to grab major Arthralgia market share @ Arthralgia Treatment Market Arthralgia Market Strengths Increased prevalence, growth in awareness, and lifestyle changes have necessitated changes in the diagnosis and treatment of PsA in the recent decade Various screening tools, including self-administered questionnaires, have been developed to help dermatologists, rheumatologist, and general physicians to identify patients who might suffer from PsA Arthralgia Market Unmet Needs Lack of biomarkers Challenges in current treatment options Challenges in current guidelines Poor disease understanding Challenges in managing comorbidities Scope of the Arthralgia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Arthralgia Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others Key Arthralgia Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others Arthralgia Therapeutic Assessment: Arthralgia current marketed and Arthralgia emerging therapies Arthralgia Market Dynamics: Arthralgia market drivers and Arthralgia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Arthralgia Unmet Needs, KOL's views, Analyst's views, Arthralgia Market Access and Reimbursement Table of Contents 1. Arthralgia Market Report Introduction 2. Executive Summary for Arthralgia 3. SWOT analysis of Arthralgia 4. Arthralgia Patient Share (%) Overview at a Glance 5. Arthralgia Market Overview at a Glance 6. Arthralgia Disease Background and Overview 7. Arthralgia Epidemiology and Patient Population 8. Country-Specific Patient Population of Arthralgia 9. Arthralgia Current Treatment and Medical Practices 10. Arthralgia Unmet Needs 11. Arthralgia Emerging Therapies 12. Arthralgia Market Outlook 13. Country-Wise Arthralgia Market Analysis (2019–2032) 14. Arthralgia Market Access and Reimbursement of Therapies 15. Arthralgia Market Drivers 16. Arthralgia Market Barriers 17. Arthralgia Appendix 18. Arthralgia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
07-04-2025
- Entertainment
- Yahoo
Art Garfunkel of Simon & Garfunkel Reveals Longtime Health Struggle
While legendary musician of Simon & Garfunkel has stayed mostly out of the public eye recently, the 83-year-old Grammy winner is speaking out at last about something he's secretly struggled with for decades. In a new interview with People, Garfunkel revealed that he's been "quietly" fighting psoriasis for a long time — but he's finally ready to open up about the uncomfortable condition. 🎬 SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox 🎬 "Psoriasis is something I lived with quietly for many years. It was part of my life even during my most public moments, including on tours, but I rarely, if ever, spoke about it," Garfunkel said. "I found ways to cover it on stage, in photos and in my day-to-day life. It's not something people would have known by looking at me, but it was always there, under the surface. I am just glad it never made its way into the music." Garfunkel went on to detail the various remedies he tried throughout his life, with little to no success. "My treatment journey was long, and it wasn't easy. Over the course of decades, I tried many approaches — different creams, remedies, even treatments involving UV light and tar," he said. "I remember being completely covered in tar; what a mess. Some gave me temporary relief, but nothing really lasted — it was a frustrating cycle." Finally, Garfunkel was introduced to the biologic ILUMYA by his dermatologist. "After my first few doses, my skin began to clear up, and for the first time in a long time, I didn't feel the need to hide. Life started to change for me," he said. The treatment was such a game changer for Garfunkel that he felt compelled to spread the word. "With a treatment that works for me, and the support from the love of my life, Kim, and the rest of my family, I am in a different place," he said. "I realized that sharing my story might help someone else who is still in the thick of it. By revealing my story, I want to reach someone who is struggling with psoriasis and let them know you are not alone and that there is hope to place psoriasis in the rearview mirror of your life." Garfunkel even put out an LP with his son, Art Garfunkel Jr., in November 2024, titled Father and Son. "I have such a wonderful family — my wife Kim and our two beautiful sons, AJ and Beau, are fantastic," he said. "We even perform together now, which is such a joy. Sharing the stage with them — and doing it while feeling fully comfortable in my skin — has brought me a whole new kind of peace. I am ready for everything good."
Yahoo
04-04-2025
- Entertainment
- Yahoo
Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis for The First Time in Partnership with Sun Pharma
8X Grammy Award-winning artist and Rock and Roll Hall of Fame inductee reveals his experience with ILUMYA®(tildrakizumab-asmn) as part of the "I LUV YA for The Long Haul" campaign. PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- Today, Sun Pharma announced its partnership with music icon and ILUMYA® (tildrakizumab-asmn) patient, Art Garfunkel, as he shares his story of living with moderate-to-severe plaque psoriasis in-depth for the first time publicly. Art, who was named one of Rolling Stone's "100 Greatest Singers of All Time," launched his career in the acclaimed duo "Simon & Garfunkel." Through the "I LUV YA for The Long Haul" campaign, Art joins a community of ILUMYA patients shedding light on the emotional toll of psoriasis and empowering others living with the condition to find the best treatment for them. While nearly 8 million Americans live with plaque psoriasis, its impact is often unseen or covered up.1 Art, whose music has touched millions worldwide, lived silently with his psoriasis—until now. "With support from my wife, Kim, and a treatment I trust, I am finally ready to give my history with psoriasis a voice," said Art. "After struggling for decades, I finally started ILUMYA about two years ago, and experiencing clearer skin has helped me regain my confidence. I am excited to share my story as part of the I LUV YA campaign in the hope that it will encourage others to find the right treatment for them." The "I LUV YA for The Long Haul," originally launched in May 2024, highlights the emotional impact psoriasis can have on a patient's life and how support – whether that be from a doctor, friend, or family member – can help navigate the challenges of managing their condition. The multi-part video series highlights real-life patient stories, including Art and how his wife, Kim, provided that support for him. "We are so honored to partner with Art Garfunkel to share his ILUMYA story and to bring greater awareness to the impact psoriasis has beyond the physical symptoms," said Maureen Shannon, Head of Biologics Marketing at Sun Pharma. "Art's music has impacted millions and his experience, shared for the first time, is sure to leave a lasting impression." To learn more about Art Garfunkel's experience and to learn more about ILUMYA as a treatment option, visit About Plaque Psoriasis Plaque psoriasis is a chronic, autoimmune disease that results in an overactive immune system and causes inflammation in the body, leading to symptoms like plaques, redness and flakes. It is estimated that nearly 8 million Americans live with plaque psoriasis.1 In plaque psoriasis, skin cells grow more rapidly than normal, rising to the surface of the skin in days rather than weeks. Life with plaque psoriasis can also be more than the physical symptoms – there can be an emotional impact as well. About ILUMYA (tildrakizumab-asmn) ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in Australia and Japan, and under the brand name ILUMETRI® in Europe, where it is marketed by Almirall. INDICATIONS AND USAGE ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONSILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients. IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONSHypersensitivityCases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. InfectionsILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves. Pretreatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment. ImmunizationsPrior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines. Adverse ReactionsThe most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea. Please see Full Prescribing Information. About Sun Pharmaceutical Industries LimitedSun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as Global Emerging Markets. Sun's high-growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit & follow us on LinkedIn & X (Formerly Twitter). DisclaimerStatements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. References View original content to download multimedia: SOURCE Sun Pharmaceutical Industries Inc., USA (Sun Pharma) Sign in to access your portfolio
